Reducing off-target drug accumulation by exploiting a type-III interferon response.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Immunology

Background:

• Nanomedicines show promise for cancer therapy but face challenges with off-target accumulation.
• Current strategies often focus on enhancing tumor delivery, neglecting off-target effects.

Purpose of the Study:

• To investigate a novel strategy for reducing off-target nanomedicine accumulation.
• To explore the potential of virus-like particles (lipoplexes) to modulate the immune response for improved nanomedicine delivery.

Main Methods:

• Administered virus-like particles (lipoplexes) followed by nanoparticles (dextran and Doxil®) 24 hours later.
• Assessed nanoparticle deposition in major organs, plasma, and tumors.
• Investigated the role of interferon lambda (IFN-λ) in mediating the observed effects.

Main Results:

• Lipoplex pre-injection significantly reduced nanoparticle deposition in major organs.
• A concurrent increase in nanoparticle accumulation in plasma and tumors was observed.
• Direct injection of interferon lambda (IFN-λ) mimicked the effect, indicating its central role.

Conclusions:

• Virus-like particles can initiate an anti-viral innate immune response that limits off-target nanomedicine accumulation.
• Interferon lambda (IFN-λ) plays a key role in this immune response, reducing deposition in non-tumor tissues.
• This approach offers a new strategy to improve the safety and efficacy of nanomedicines in cancer therapy.